Skip to main content
Top
Published in: Familial Cancer 1/2011

01-03-2011

Strictly defined familial male breast cancer

Authors: Uwe Güth, Dieter Müller, Dorothy Jane Huang, Ellen Obermann, Hansjakob Müller

Published in: Familial Cancer | Issue 1/2011

Login to get access

Abstract

The term “familial male breast cancer” is often misleading, because in the breast cancer families reported in the literature, the vast majority of the patients were women and only a few were men. In this report, we present the rare case of a strictly defined familial male breast cancer (MBC) in which exclusively men were diagnosed with breast cancer. Three of four brothers developed the disease between the age of 46 and 64 years within a period of 21 years whereas all female relatives remained unaffected. The three affected men did not show the typical known clinical and genetic risk factors for MBC. An X-linked recessive inheritance may be possible in these cases. One way to potentially improve the identification of the causes of MBC could be a through a strictly studying families in which the male members were exclusively diagnosed with this malignancy. This approach emphasizes familial MBC as a distinct entity and not only as a variant of female breast cancer.
Literature
2.
go back to reference Giordano SH (2005) A review of the diagnosis and management of male breast cancer. Oncologist 10:471–479CrossRefPubMed Giordano SH (2005) A review of the diagnosis and management of male breast cancer. Oncologist 10:471–479CrossRefPubMed
3.
go back to reference Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122CrossRefPubMed Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122CrossRefPubMed
4.
go back to reference Lanitis S, Rice AJ, Vaughan A et al (2008) Diagnosis and management of male breast cancer. World J Surg 32:2471–2476CrossRefPubMed Lanitis S, Rice AJ, Vaughan A et al (2008) Diagnosis and management of male breast cancer. World J Surg 32:2471–2476CrossRefPubMed
5.
go back to reference Onami S, Ozaki M, Mortimer JE, Pal SK (2010) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65:308–314CrossRefPubMed Onami S, Ozaki M, Mortimer JE, Pal SK (2010) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65:308–314CrossRefPubMed
6.
go back to reference Couch FJ, Farid LM, DeShano ML et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123–125CrossRefPubMed Couch FJ, Farid LM, DeShano ML et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123–125CrossRefPubMed
7.
go back to reference Evans DG, Bulman M, Young K et al (2001) High detection rate for BRCA2 mutations in male breast cancer families from North West England. Fam Cancer 1:131–133CrossRefPubMed Evans DG, Bulman M, Young K et al (2001) High detection rate for BRCA2 mutations in male breast cancer families from North West England. Fam Cancer 1:131–133CrossRefPubMed
8.
go back to reference Evans DG, Bulman M, Young K et al (2008) BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 7:113–117CrossRefPubMed Evans DG, Bulman M, Young K et al (2008) BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 7:113–117CrossRefPubMed
9.
go back to reference Miolo G, Puppa LD, Santarosa M et al (2006) Phenotypic features, genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer 6:156CrossRefPubMed Miolo G, Puppa LD, Santarosa M et al (2006) Phenotypic features, genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer 6:156CrossRefPubMed
10.
go back to reference Tournier I, Paillerets BB, Sobol H et al (2004) Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64:8143–8147CrossRefPubMed Tournier I, Paillerets BB, Sobol H et al (2004) Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64:8143–8147CrossRefPubMed
11.
12.
13.
14.
go back to reference Jones C, Oliver DJ, Van Merwyk AJ (1996) Familial male breast cancer. Med J Aust 164:640PubMed Jones C, Oliver DJ, Van Merwyk AJ (1996) Familial male breast cancer. Med J Aust 164:640PubMed
15.
go back to reference Schwartz RM, Newell RB Jr, Hauch JF, Fairweather WH (1980) A study of familial male breast carcinoma and a second report. Cancer 46:2697–2701CrossRefPubMed Schwartz RM, Newell RB Jr, Hauch JF, Fairweather WH (1980) A study of familial male breast carcinoma and a second report. Cancer 46:2697–2701CrossRefPubMed
16.
go back to reference Sodha N, Wilson C, Bullock SL et al (2004) Analysis of familial male breast cancer for germline mutations in CHEK2. Cancer Lett 215:187–189CrossRefPubMed Sodha N, Wilson C, Bullock SL et al (2004) Analysis of familial male breast cancer for germline mutations in CHEK2. Cancer Lett 215:187–189CrossRefPubMed
17.
go back to reference Edge S, Byrd D, Compton C et al (2009) AJCC cancer staging manual. Springer, New York Edge S, Byrd D, Compton C et al (2009) AJCC cancer staging manual. Springer, New York
18.
go back to reference Sobin L, Gospodarowicz M, Wittekind C (eds) (2009) UICC: TNM classification of malignant tumors. Wiley-Blackwell, Oxford Sobin L, Gospodarowicz M, Wittekind C (eds) (2009) UICC: TNM classification of malignant tumors. Wiley-Blackwell, Oxford
19.
go back to reference Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158CrossRefPubMed Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158CrossRefPubMed
20.
go back to reference Zanna I, Rizzolo P, Sera F et al (2010) The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. Eur J Hum Genet 18:856–858CrossRefPubMed Zanna I, Rizzolo P, Sera F et al (2010) The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. Eur J Hum Genet 18:856–858CrossRefPubMed
21.
go back to reference Meindl A, Hellebrand H, Wiek C et al (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42:410–414CrossRefPubMed Meindl A, Hellebrand H, Wiek C et al (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42:410–414CrossRefPubMed
22.
go back to reference Neuhausen S, Dunning A, Steele L et al (2004) Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108:477–478CrossRefPubMed Neuhausen S, Dunning A, Steele L et al (2004) Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108:477–478CrossRefPubMed
23.
go back to reference Offit K, Pierce H, Kirchhoff T et al (2003) Frequency of CHEK2*1100delC in New York breast cancer cases, controls. BMC Med Genet 4:1CrossRefPubMed Offit K, Pierce H, Kirchhoff T et al (2003) Frequency of CHEK2*1100delC in New York breast cancer cases, controls. BMC Med Genet 4:1CrossRefPubMed
24.
go back to reference Ohayon T, Gal I, Baruch RG et al (2004) CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108:479–480CrossRefPubMed Ohayon T, Gal I, Baruch RG et al (2004) CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 108:479–480CrossRefPubMed
25.
go back to reference Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108:475–476CrossRefPubMed Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108:475–476CrossRefPubMed
26.
go back to reference Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167CrossRefPubMed Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167CrossRefPubMed
27.
go back to reference Sauty de Chalon A, Teo Z, Park DJ et al (2010) Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 121:253–255CrossRefPubMed Sauty de Chalon A, Teo Z, Park DJ et al (2010) Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 121:253–255CrossRefPubMed
28.
go back to reference Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Mol Oncol 4:174–191CrossRefPubMed Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M (2010) Genetic susceptibility to breast cancer. Mol Oncol 4:174–191CrossRefPubMed
29.
go back to reference Eden JA (2010) Breast cancer, stem cells and sex hormones Part 1. The impact of fetal life and infancy. Maturitas 67:117–120CrossRefPubMed Eden JA (2010) Breast cancer, stem cells and sex hormones Part 1. The impact of fetal life and infancy. Maturitas 67:117–120CrossRefPubMed
30.
go back to reference Ruder EH, Dorgan JF, Kranz S et al (2008) Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin Breast Cancer 8:334–342CrossRefPubMed Ruder EH, Dorgan JF, Kranz S et al (2008) Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin Breast Cancer 8:334–342CrossRefPubMed
Metadata
Title
Strictly defined familial male breast cancer
Authors
Uwe Güth
Dieter Müller
Dorothy Jane Huang
Ellen Obermann
Hansjakob Müller
Publication date
01-03-2011
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9400-3

Other articles of this Issue 1/2011

Familial Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine